TranscainideAlternative Names: R 54718
Latest Information Update: 02 Apr 1997
Price : $50
At a glance
- Originator Janssen L.P.
- Class Class Ic antiarrhythmics
- Mechanism of Action Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 02 Apr 1997 No-Development-Reported for Arrhythmias in Belgium (IV)
- 02 Apr 1997 No-Development-Reported for Arrhythmias in Belgium (PO)
- 24 Oct 1994 Phase-II clinical trials for Arrhythmias in Belgium (IV)